Custom Search


Wednesday 31 October 2007

A novel camptothecin analog with enhanced antitumor activity.

By: Yount G, Yang Y, Wong B, Wang HJ, Yang LX.

Anticancer Res 2007 Sep-Oct;27(5A):3173-8

BACKGROUND: The use of camptothecin (CPT) derivatives is limited by severe toxicity associated with the instability of their chemical structure. We have developed a stable CPT derivative (CPT417) and have investigated its biological activity in comparison to the currently used CPT analogs. MATERIALS AND METHODS: The anticancer effects of CPT417 were assessed in vitro, with glioblastoma and colon cancer cell lines, and in vivo with mice bearing mammary adenocarcinoma tumors implanted subcutaneously in the flank. Cytotoxicity was assessed using vital dye exclusion, timelapse microscopy and colony formation. RESULTS: CPT417 and topotecan inhibited glioblastoma cell growth at comparable levels and both compounds inhibited clonogenicity of colon cancer cells more effectively than irinotecan. CPT417 showed a much greater inhibition of mammary tumor growth compared to topotecan, both by intraperitoneal and oral administration. CONCLUSION: CPT417 shows dramatically reduced toxicity and an enhanced antitumor activity compared to topotecan.

Use of this site is subject to the following terms of use